Introduction
Numerous structures of glycans have been found in various forms of glycoconjugates, including both secreted and membrane-integrated glycoproteins (Taylor and Drickamer 2003) . Increasing attention is being paid to the development of biological pharmaceutics represented by immunoglobulin and erythropoietin, which are basically secreted glycoproteins. Glycan moieties are often critical for the stability and efficacy of these glycoprotein drugs, because glycans play many important roles in biological phenomena (Dietl and Rauth 1989; Dabelsteen 1996; Taylor and Drickamer 2003; Gascon et al. 2007) . Although glycoproteins themselves are originally heterogeneous through the presence of different glycoforms, several attempts have been recently made to produce pharmaceutical recombinant glycoproteins carrying a single, defined glycan structure with the expectation of a better performance in various aspects, such as stability, target specificity and efficacy of the drugs. However, for both natural chemical ligation (Kajihara et al. 2006 ) and the chemo-enzymatic approach using endo-β-N-acetylglucosaminidase (Huang et al. 2009; Yamamoto 2001; Schwarz et al. 2010; Umekawa et al. 2010; Fisher et al. 2011) , a large amount of homogeneous glycan is needed as a synthetic donor substrate. In this context, glycan supply is a bottleneck in producing glycoprotein drugs (i.e. glycobiologics).
In our previous studies, a basis for preparing a series of human-type (or human-compatible) N-glycans was developed under the concept "strategic glycan maps", and efforts have so far been concentrated on hen eggs (Sumiyoshi et al. 2009 ) and those of other pheasant species (Sumiyoshi et al. 2010) . In fact, avian eggs are constantly available in markets, and most of their glycan structures have proved to be identical to those of humans. On the other hand, it was also found that avian eggs lack several kinds of glycans, e.g. those having core-fucose and α2,3-Sia residues, which represent major structural epitopes in human that are often associated with important biological functions of glycoproteins. Therefore, it is necessary to pioneer useful sources of glycans other than avian eggs. For this purpose, mammalian sera are considered as good sources containing considerable amounts of glycoproteins secreted from diverse origins that produce different glycomes. Moreover, some of them (e.g. IgG, fetuin and transferrin) have been well characterized (Tai et al. 1975; Spik et al. 1988; Cumming et al. 1989; Raju et al. 2000) .
Another important issue in glycobiologics is the elimination of non-human-type (i.e. antigenic) glycans, which can be contaminants or can be produced during the course of animal cell cultivation using animal sera. Typical examples of such xenogeneic glycans are the αGal epitope and glycolyl-type sialic acid (NeuGc), which humans do not produce. In this regard, xenotransplantation has been of special concern in clinical science, because it can cause hyperacute rejection in recipients (Zhu and Hurst 2002; Diswall et al. 2010) . Although the αGal epitope represents a typical cause of hyperacute rejection, inclusion of NeuGc in glycoproteins such as IgG is an emerging issue in current biologics (Ghaderi et al. 2010) . Basnet et al. (2010) recently reported that the deficiency of these antigenic glycans in xenogeneic cells can lower the risk of cytotoxicity induced by human natural antibodies.
At present, we cannot exclude possibility that there are other xenogeneic antigen(s) that have not yet been identified in animal tissues and sera. In this sense, it is a pressing issue to reinvestigate animal glycomes more thoroughly from the viewpoint of both glycobiologics and comparative glycomics. In this work, we initially intended to search extensive mammalian sera for human-type N-glycans not present in avian eggs. As a result, however, we found that sera from cow, lamb and goat belonging to the order Artiodactyla contain unusual hypersialylated glycans that are not found in sera from other mammalian orders ( pig, horse and human).
Results
Preparation of pyridylaminated N-glycans from bovine serum Pyridylaminated (PA) N-glycans were prepared from bovine serum as described in Materials and methods. Briefly, purified PA glycans were first fractionated by anion-exchange chromatography on a Q-Sepharose column (16 × 115 mm). The neutral glycan fraction designated "N", and the adsorbed anionic fractions designated A 1 4 according to the elution order (Supplementary data, Figure S1 ) were subjected to further purification by reversed-phase (RP) chromatography on a COSMOSIL 5C18-P column (10 × 250 mm). The chromatography was initially performed with a high concentration of 1-butanol, i.e. 0.5% (v/v) in 100 mM ammonium acetate ( pH 4.0; Supplementary data, Figure S2 ), and then with a lower concentration (i.e. 0.1-0.4%) of 1-butanol in 20 mM ammonium acetate ( pH 4.0) according to the elution positions in the first round of chromatography (Supplementary data, Figure S3 ). For instance, N-5 gave retention times corresponding to high-mannose-type glycans in the first round of chromatography and were further separated with 0.1% 1-butanol, whereas N-12, whose elution position corresponded to a group of biantennary complex-type glycans, was further separated with 0.2% 1-butanol. Some fractions needed an additional separation process: the A1-11 fraction gave an apparently single peak in RP-high-performance liquid chromatography (HPLC; 0.2% of 1-butanol), but four peaks were observed by normal-phase (NP) chromatography on an Inertsil NH2 column (4.6 × 150 mm) and were further purified by this mode of chromatography (data not shown).
Analysis and quantification of normal-type structures of bovine serum N-glycans The structures of the purified glycans were analyzed and quantified on the basis of fluorescence intensity relative to an appropriate quantity-defined authentic standard glycan. As a result, 18 neutral glycans and 16 sialylated glycans were isolated from bovine serum glycoproteins, among which six acidic glycans were not directly identified as any known structure (#43-48). Among the complex-type glycans, biantennary structures were apparently the major components, although five high-mannose-type glycans were also detected. On the other hand, hybrid-type glycans were not detected, at least as major components, among the bovine glycoproteins (Tables I-III and Figure 1) .
The dominant neutral glycoforms of bovine serum were two core-fucosylated complex-type glycans, BIF-Gii (#13, 240 nmol/g of the starting material) and BIF (#14, 500 nmol/g). Other neutral complex-type glycans detected in significant quantity included BI (#10, 87 nmol/g), BIF-2G (#11, 120 nmol/g) and BIF/Bs-2G (#19, 87 nmol/g). Acidic (sialylated) glycans are structurally more variable in terms of the type of sialylation linkage (α2-3 or α2-6), in addition to corefucosylation, although their structures were confined to sialylated biantennary glycans. The most abundant sialylated glycan was 2SiaBIi (#37, 280 nmol/g). A series of α-galactosylated glycans was also detected among both neutral and acidic glycans (#15, 32 and 33), the structures of which were determined by susceptibility to α-galactosidase digestion. In addition to these expected structures, a significant number of unexpected glycans (#43-48, Table III) were observed in this study: all of them showed data implying excessively sialylated, biantennary glycans in matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS).
Structural determination of hypersialylated biantennary N-glycans found in bovine serum As described, bovine serum glycoproteins contained a substantial amount of biantennary glycans with excess amounts of Sia residues relative to galactose (i.e. hypersialylated glycans), which were further classified as trisialo-type (#43-47) and tetrasialo-type (#48). Structural analysis of the former (#43-47) was performed by sequential glycosidase digestion, which included partial sialidase digestion, according to Scheme 1. Each glycan (1 nmol) was first subjected to partial sialidase digestion with 1 mU of neuraminidase from Arthrobacter ureafaciens, which acts on all Sia linkages, i.e. α2-3, α2-6 and α2-8 (Ohta et al. 1989) . Results of a typical digestion for glycan #45 are shown in Figure 2 . Three structural isomers with a single Sia residue were isolated by RP chromatography and were sequentially digested with β-galactosidase, β-N-acetylhexosaminidase, α2,3-specific sialidase and a non-specific neuraminidase to obtain a trimannosylcore with GlcNAc (for a typical case; see Figure 2 for W Sumiyoshi et al. Table I . Major neutral glycans identified in animal sera Hypersialylated non-human-type N-glycan in Artiodactyla sera the results of #45). The branch with a type-I structure, Galβ1,3GlcNAc, was determined by susceptibility to lacto-N-biosidase after all Sia residues had been removed.
We also obtained a tetrasialo-type biantennary glycan (i.e. two excess Sia residues relative to Gal; #48). Because glycan #48 was sensitive to α2,3-specific sialidase and the resultant product with two Sia residues was susceptible to β-galactosidase treatment, it was concluded that two of the four Sia residues of glycan #48 were bound to Gal in an α2-3 linkage. The resultant agalactosylated glycan was resistant to β-N-acetylhexosaminidase digestion; however, non-specific neuraminidase treatment gave a glycan with HPLC and MS profiles consistent with the authentic standard BI-2G (#7). Moreover, this desialylated structure was found to be susceptible to lacto-N-biosidase digestion, resulting in a trimannosylcore structure. Therefore, it was concluded that glycan #48 was a biantennary glycan with two Galβ1,3GlcNAc residues. Considering the above results, the most likely structure of #48 can be proposed as shown in Table III .
The observed hypersialylation appears to largely depend on the presence of a type-I structure in which α2,6Sia is linked to the penultimate GlcNAc residue. Intriguingly, none of the common types of sialylated (#23-42) or non-sialylated saccharides (#1-22) comprise a type-I structure.
Structural analysis and quantification of N-glycans of other mammalian sera N-Glycans were also prepared from the sera of four other mammalian species, namely, pig (PS), lamb (LS), horse (HS) and goat (GS). All of their structures (as listed in Tables I-III) were determined by a procedure similar to that taken for bovine serum. In addition, Figure 1 features the structural profiles of individual animal sera. The most abundant glycan in bovine serum was core-fucosylated biantennary complex-type N-glycan (#14, designated BIF). Although this glycan was present in all of the other animal sera tested, it was not a major species in any of them: the dominant species was either the α2-6disialylated form of BIF (#39, 2SBIFi) in porcine serum or its non-core-fucosylated form (#37, 2SBIi) in lamb, horse and goat sera. The agalactosylated form of BIF (#11, BIF-2G) was also abundant in porcine and horse sera.
Glycans containing bisected GlcNAc (#17-22) were somewhat evident in bovine, lamb and goat sera. A significant amount of αGal-containing glycan (#15, 2GBI) was present in bovine, porcine and lamb sera, but not in horse or goat sera. Hybrid-type glycans (#23 and 24) were very minor components, if present at all (lamb, goat and porcine sera). Apparently, the detected glycans were structurally related to one another in the context of N-glycan biosynthesis. The hypersialylated glycans observed in bovine serum were also found in sera from animals of the same order Artiodactyla, namely lamb and goat, but not in sera from pig and horse, the latter belonging to another order Perissodactyla. In Table IV , the structural features of glycans in each animal serum are summarized in terms of (i) high-mannose/hybrid/complex types, (ii) neutral/acidic, (iii) α2-3/α2-6Sia, (iv) αGal, (v) core-Fuc, (vi) bisecting GlcNAc, (vii) type-I/II and (viii) hypersialylation. Apparently, hypersialylation is closely associated with the presence of a type-I lactosamine structure, as well as the absence of core-fucosylation (Table III) .
Discussion
We previously proposed the development of a series of strategic glycan maps as a basis for producing various kinds of human-type N-glycans. Despite our efforts in egg white and yolk of pheasant species including hen, it turned out that these biological sources did not contain human-type N-glycans with core-fucose and α2,3-Sia residues (Sumiyoshi et al. 2010) . In this study, we investigated mammalian sera as new sources of glycans and found that mammalian sera contained glycans with core-fucose and α2,3-Sia residues as Table III . Hypersialylated glycans identified in animal sera *Oligosaccharides that were detected in bovine prothrombin by Mizuochi et al. (1979) .
Hypersialylated non-human-type N-glycan in Artiodactyla sera major components, consistent with previous reports (Kita et al. 2007 ). Among the sera compared, porcine serum contained the greatest amount of core-fucosylated glycans (87% of total glycans) as represented by 2SBIFi (#39). Representative xenoantigenic glycans containing an α-Gal epitope (Galα1,3Gal) were also found in bovine, porcine and lamb sera, but were not detected in horse or goat sera (#15 in Table I and #32 and #33 in Table II) .
Unexpectedly, significant amounts of hypersialylated glycans, which have excess Sia residues relative to Gal residues, were detected in the sera of some animals, namely cow, lamb and goat belonging to the order Artiodactyla (the so-called even-toed ungulates), but not in those of other animals, pig and horse, belonging to Artiodactyla and Perissodactyla, respectively. These glycans have been previously found in some purified glycoproteins such as bovine Fig. 1 . Comparison of yields of N-glycans prepared from mammalian sera. The following monosaccharide symbols are used to express glycan structures: green circle, Man; blue square, GlcNAc; yellow circle, Gal; purple diamond, NeuAc; red triangle, Fuc. Numbers on the vertical axis show the yield from 1 g of acetone powder. The numbers on the horizontal axis are Sugar ID numbers corresponding to those defined in Tables I-III. W Sumiyoshi et al. fetuin and prothrombin (Mizuochi et al. 1979; Cumming et al. 1989) and have one or two type-I (Galβ1,3GlcNAc) structures in conjunction with the unusual NeuAcα2,6GlcNAc linkage (Table III) . From the results of the present study, as well as the previous reports that the sialyltransferase that transfers Sia to the GlcNAc residue of the Galβ1,4GlcNAc unit is not present in these animals (Harduin-Lepers et al. 1995 , 2005 , it appears that the presence of a type-I lactosamine unit is prerequisite for this hypersialylation. Neither hypersialylated glycans nor biantennary glycans with the Galβ1,3GlcNAc unit were found in the sera of cancer patients (Morelle et al. 2006; Kita et al. 2007; Alley et al. 2010) . Therefore, it has been suggested that β3-galactosyltransferase that synthesizes the type-I Galβ1,3GlcNAc unit in N-glycans is more or less absent in human tissues except for some specific organs, such as the brain and heart (Amado et al. 1998; Kolbinger et al. 1998) . We used a similar approach to search for hypersialylated glycans in the serum of a healthy human volunteer; however, such glycans were not detected under the experimental conditions used (i.e. limit of detection, 0.5 nmol/g acetone powder; Supplementary data, Figure S4 ). It should also be mentioned that the sialic acid identified in this study might result, in part, from N-glycolylneuraminic acid (another xenoantigenic glycan epitope) in the original sera, because N-glycolylneuraminic acid is chemically converted to N-acetylneuraminic acid during the course of hydrazinolysis and subsequent re-acetylation. The present results raise the possibility that hypersialylated N-glycans containing the Galβ1,3(NeuAcα2,6)GlcNAc structure are novel xenoantigens. As far as we know, they are non-human-type glycans originating from a specific group of mammals belonging to Artiodactyla, e.g. cow, lamb and goat. If these saccharides are antigenic to human, their attachment to or contamination of pharmaceutical drugs produced in appropriate animal cells or from sera may induce undesirable immunological reactions similar to the α-Gal epitope and N-glycolylneuraminic acid. The present finding of hypersialylated structures only in Artiodactyla and not in other orders [i.e. Perissodactyla (horse) and Primate (human)] is intriguing from the viewpoint of glycobiological evolution. For this reason, there is possibility that horse serum is useful in the production of biological pharmaceutics from a standpoint of the glyco-xenoantigen compared with the sera of other animals. On the other hand, glycans with a Galβ1,3(NeuAcα2,6)GlcNAc structure have previously been reported in human milk and mucosal membranes of human digestive organs (Sumiyoshi et al. 2003; Kannagi 2006; Asakuma et al. 2007) . In this context, sialyltransferase, which catalyzes the transfer of sialic acid to GlcNAc, has been characterized in human liver (de Heij et al. 1986) . Notably, human milk contains a relative abundance of glycans with a type-I (Galβ1-3GlcNAc) structure, whereas this structure is totally absent from tissues and serum or, if it is present, it is extremely rare, as described previously (Amado et al. 1998; Kolbinger et al. 1998) . Another explanation is that the hypersialylated structures are synthesized if appropriate β3-galactosyltransferases are sufficiently expressed in some situations (e.g. disease states and developmental stages). Also of note is the striking resemblance of the investigated hypersialylated tetrasaccharide to a major O-glycan, NeuAcα2,3Galβ1,3(NeuAcα2,6)GalNAc, commonly called disialyl T. Thus, it is possible to speculate that the sialyltransferases involved in disialyl T synthesis might erroneously Scheme 1. Procedure for structural determination of hypersialylated glycans.
Hypersialylated non-human-type N-glycan in Artiodactyla sera (or unstably) transfer the second NeuAc residue to NeuAcα2,3Galβ1,3GlcNAc (ST6GalNAc transferase-like activity) instead of NeuAcα2,3Galβ1,3GalNAc to a certain extent in Artiodactyla. At the moment, responsible enzymes have not been identified in this order of animals. Moreover, the antigenicity of the hypersialylated structures to human is not known. Of further glycobiological interest is the recognition of the type-I lactosamine-containing hypersialylated structure by lectins, because it is known that MAH plant lectin shows high affinity for the disialyl T structure (Konami et al. 1994; Yim et al. 2001) . Glycan structures are so divergent that further study is necessary to investigate more thoroughly animal glycans from both a practical and a biological point of view. 
Materials and methods

Materials
Sera of cow, pig, lamb, horse and goat were purchased from GIBCO (Carlsbad). 2-Aminopyridine was obtained from Nacalai Tesque (Kyoto, Japan) and purified with heptane. Anhydrous hydrazine was provided by Masuda Chemical Industries (Kagawa, Japan), and Dowex 50WX8 (200-400 mesh, H + form) was purchased from Muromachi Technos (Tokyo, Japan). Q-Sepharose and cellulose microcrystalline were obtained from GE Healthcare (Amersham, UK) and Merck (Darmstadt, Germany), respectively. TSK gel Toyopearl HW-40F, a Cosmosil 5C18-P column (10 × 250, 4.6 × 150 and 2 × 250 mm) and an Inertsil NH2 column (4.6 × 150 mm) were from Tosoh (Tokyo, Japan), Nacalai Tesque and GL Sciences (Tokyo, Japan), respectively. Shodex Asahipak NH2P-50 2D column (2 × 150 mm) was from Showa Denko (Tokyo, Japan). Neuraminidase from A. ureafaciens was purchased from Nacalai Tesque. α-2,3-Sialidase cloned from Salmonella typhimurium LT2 and expressed in Escherichia coli, and lacto-N-biosidase were from Takara Bio (Shiga, Japan). α-L-Fucosidase from bovine kidney was obtained from Sigma-Aldrich (Tokyo, Japan). β-Galactosidase and β-N-acetylhexosaminidase from jack bean were obtained from Seikagaku Corporation (Tokyo). α-Galactosidase from green coffee beans was obtained from Sigma-Aldrich. 2,5-Dihydroxybenzoic acid was obtained from Bruker Daltonics (Billerica, MA). Methanol, acetonitrile and 1-butanol were of HPLC grade, whereas the other chemicals were of analytical grade. All other standard PA N-glycans were prepared as described previously (Nakakita et al. 1999; Sumiyoshi et al. 2009 Sumiyoshi et al. , 2010 .
Liberation of N-glycans and pyridylamination of mammalian sera An equal volume of methanol and chloroform was added to each serum, and the extracts were centrifuged (2000 × g, 30 min, 4°C using a Tomy RL-131 centrifuge, Tomy Seiko Co., Tokyo, Japan). An equal volume of acetone was added to the pellet, and after centrifugation, the pellets obtained were lyophilized as acetone powder. The fractions (150 mg each) were then equally divided into three glass tubes with screw-cap lids (each containing 50 mg powder). To each tube was added 5 mL of anhydrous hydrazine and the tube was then heated to 100°C for 10 h, as described previously (Yosizawa et al. 1966; Takasaki et al. 1982) . After hydrazinolysis, the liberated N-glycans were N-acetylated, desalted with Dowex 50WX8 and lyophilized.
The fractions obtained were PA essentially by the method of Hase et al. (1978) and Hase (1994) . Briefly, lyophilized N-glycan fractions were dissolved in 1.5 mL of the coupling reagent (2.76 g of 2-aminopyridine in 1 mL of acetic acid) and heated at 90°C for 60 min in a heating block. After the coupling reaction, 5.25 mL of freshly prepared reducing Table IV . Summary of structural features of N-glycans identified in animal sera Hypersialylated non-human-type N-glycan in Artiodactyla sera reagent (6 g of dimethylamine-borane in 2.4 mL of acetic acid and 1.5 mL of water) was added, and the mixture was heated at 80°C for 35 min. The reaction was extracted with a watersaturated phenol/chloroform solution (Tokugawa et al. 1996) , and PA fractions were applied to a Toyopearl HW-40F column (2.5 × 38 cm) equilibrated with 10 mM ammonium acetate ( pH 6.0) in order to remove excess reagents (Kuraya and Hase 1992) .
Purification of PA N-glycans of mammalian sera The fractions obtained were first desalted on a cellulose column (1 mL bed volume; Shimizu et al. 2001 ). The desalted fractions were then subjected to anion exchange chromatography using a Q-Sepharose column (16 × 115 mm) equilibrated with distilled water titrated to pH 9.0 with 7 M aqueous ammonia. After 10 min, the proportion of 0.5 M ammonium acetate buffer ( pH 9.0) was increased with a linear gradient from 0 to 40% over 30 min (flow rate of 3.0 mL/min).
The neutral and acidic glycan fractions obtained were subjected to preliminary fractionation by RP-HPLC under isocratic conditions. Specifically, we used a Cosmosil 5C18-P column (10 × 250 mm) equilibrated with 100 mM ammonium acetate buffer ( pH 4.0) containing 0.5% (v/v) 1-butanol at a flow rate of 3.0 mL/min. The fractions obtained were then subjected to fine fractionation under different isocratic conditions with 20 mM ammonium acetate buffer ( pH 4.0) containing an appropriate concentration (0.1-0.5%) of 1-butanol at a flow rate of 3.0 mL/min. Fractions that did not give a clear single peak in a test run were subjected to further purification by NP-HPLC with an Inertsil NH2 column (4.6 × 150 mm) equilibrated with acetonitrile containing 0.03% (v/v) ammonium formate buffer ( pH 4.4). After the injection of a sample dissolved in the equilibration buffer, the proportion of ammonium formate buffer was increased with a linear gradient from 0.03 to 0.06% in 10 min and from 0.06 to 0.14% in 50 min at a flow rate of 1.5 mL/min. Yields were estimated from the fluorescence intensity by comparison with an appropriate authentic standard of known concentration.
Structural analysis of PA N-glycans Purified glycans obtained in relatively high yields (i.e. >1 nmol/150 mg of acetone powder) were considered to be major glycans and were subjected to structural analysis by MALDI-TOF MS with an autoflex II mass spectrometer (Bruker Daltonics, Bremen, Germany), equipped with a 337-nm nitrogen laser and set at 20 kV extraction voltage. 2,5-Dihydroxybenzoic acid (1 mg/mL in 30% ethanol) was used as the matrix. Analyses were carried out in the reflector mode over a mass range of m/z 280 to 4080 in the positive-ion mode, and 80 to 3300 in the negative-ion mode. Each spectrum was measured by 150 laser shots.
N-Glycans that gave an MS molecular weight likely to correspond to known N-glycans were further analyzed by RP-HPLC and NP-HPLC. The analysis and quantitative determination was performed with a Cosmosil 5C18-P column (2 × 250 mm) equilibrated with 20 mM ammonium acetate buffer ( pH 4.0) containing 0.075% (v/v) 1-butanol. After the injection of a sample dissolved in the equilibration buffer, the proportion of 1-butanol was increased with a linear gradient from 0.075 to 0.425% over 90 min at a flow rate of 0.18 mL/ min. NP-HPLC was performed with a Shodex Asahipak NH2P-50 2D column (2 × 150 mm) at a flow rate of 0.1 mL/ min. The gradient system consisted of eluent A (930:70:3 acetonitrile:water:acetic acid titrated to pH 7.0 with 7 M aqueous ammonia) and eluent B (200:800:3 acetonitrile:water: acetic acid titrated to pH 7.0 with 7 M aqueous ammonia). The column was equilibrated with 80% eluent A/20% eluent B. After the injection of a sample, eluent B was increased linearly from 20 to 30% (v) in 10 min, to 60% (v) in 60 min and then to 80% (v) in 85 min.
The analysis of glycans that were partially digested by neuraminidase from A. ureafaciens was performed with a Cosmosil 5C18-P column (4.6 × 150 mm) equilibrated with 50 mM acetic acid containing 0.015% (v/v) 1-butanol. After the injection of a sample, the proportion of 1-butanol was increased with a linear gradient from 0.015 to 0.20% over 45 min at a flow rate of 1.0 mL/min.
Those glycans for which the structures could not be identified by RP-HPLC due to the absence of standard saccharides were subjected to collision-induced dissociation MS using argon as collision gas on an autoflex II mass spectrometer and, when necessary, specific glycosidase digestions. Glycosidase digestions were performed by incubation with 50 mU of glycosidases in 25 mM ammonium acetate buffer of optimum pH either overnight or for 10 min for α-2,3-sialidase or neuraminidase. Partial sialidase digestion was performed with 1 mU of neuraminidase from A. ureafaciens.
